SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine

Mice lacking suppressor of cytokine signaling-1 (SOCS1) develop a complex fatal neonatal disease. In this study, SOCS1-/- mice were shown to exhibit excessive responses typical of those induced by interferon gamma (IFNgamma), were hyperresponsive to viral infection, and yielded macrophages with an enhanced IFNgamma-dependent capacity to kill L. major parasites. The complex disease in SOCS1-/- mice was prevented by administration of anti-IFNgamma antibodies and did not occur in SOCS1-/- mice also lacking the IFNgamma gene. Although IFNgamma is essential for resistance to a variety of infections, the potential toxic action of IFNgamma, particularly in neonatal mice, appears to require regulation. Our data indicate that SOCS1 is a key modulator of IFNgamma action, allowing the protective effects of this cytokine to occur without the risk of associated pathological responses.

[1]  A. Thomson.  The cytokine handbook , 1994 .

[2]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[3]  A. Billiau,et al.  Interferon-gamma: biology and role in pathogenesis. , 1996, Advances in immunology.

[4]  J. Darnell,et al.  Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. , 1992, Science.

[5]  K Yuge,et al.  A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. , 1998, Blood.

[6]  K. Yamamura,et al.  Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Taniguchi,et al.  Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development , 1993, Cell.

[8]  O. Silvennoinen,et al.  Signaling by the cytokine receptor superfamily: JAKs and STATs. , 1994, Trends in biochemical sciences.

[9]  W. Paul,et al.  Interleukin-4 : A Prototypic Immunoregulatory Lymphokine , 2003 .

[10]  J. D. de Vries,et al.  Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. , 1994, Immunology today.

[11]  K. Okkenhaug,et al.  Socs1 binds to multiple signalling proteins and suppresses Steel factor‐dependent proliferation , 1999, The EMBO journal.

[12]  I. Mackay,et al.  Intermittent interferonemia and interferon responses in multiple sclerosis. , 1991, Clinical immunology and immunopathology.

[13]  R. Simpson,et al.  Role of interleukin-6 in T-cell activation during primary and secondary infection with Listeria monocytogenes , 1995, Infection and immunity.

[14]  S. Cohen,et al.  Induction by EGF and interferon-gamma of tyrosine phosphorylated DNA binding proteins in mouse liver nuclei. , 1993, Science.

[15]  J. Ihle,et al.  Signaling by the Cytokine Receptor Superfamily a , 1998, Annals of the New York Academy of Sciences.

[16]  J. Darnell,et al.  Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway , 1995, Science.

[17]  W. Alexander,et al.  Point mutations within a dimer interface homology domain of c‐Mpl induce constitutive receptor activity and tumorigenicity. , 1995, The EMBO journal.

[18]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[19]  B. Viviano,et al.  Ligand‐induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). , 1994, The EMBO journal.

[20]  J. Darnell,et al.  Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions , 1994, Cell.

[21]  J. Darnell,et al.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.

[22]  S. Corey,et al.  Src-related protein tyrosine kinases in hematopoiesis. , 1999, Blood.

[23]  M. Ferguson,et al.  Biosynthesis of the glycolipid anchor of lipophosphoglycan and the structurally related glycoinositolphospholipids from Leishmania major. , 1995, The Biochemical journal.

[24]  F. Chisari,et al.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis , 1993, The Journal of experimental medicine.

[25]  A. Billiau,et al.  Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock , 1991, European journal of clinical investigation.

[26]  D. Levy,et al.  Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease , 1996, Cell.

[27]  W. Fiers,et al.  Toxic effects of recombinant tumor necrosis factor in suckling mice. Comparisons with interferon alpha/beta. , 1987, The American journal of pathology.

[28]  A. Wilks,et al.  Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. , 1994, The Journal of biological chemistry.

[29]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[30]  G. Stark,et al.  Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon‐alpha and ‐gamma signal transduction pathways. , 1993, The EMBO journal.

[31]  A. Bradley,et al.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. , 1993, Science.

[32]  W. Alexander,et al.  Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL‐6 signal transduction , 1999, The EMBO journal.

[33]  R. Schreiber,et al.  IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. , 1998, The Journal of clinical investigation.

[34]  S. Pestka,et al.  Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Melmed,et al.  Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. , 1998, Molecular endocrinology.

[36]  A. Yoshimura,et al.  CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. , 1997, Blood.

[37]  E. Handman.  Association of serum proteins with cultured Leishmanial a warning note , 1983, Parasite immunology.

[38]  A. Elefanty,et al.  Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1 , 1999, Leukemia.

[39]  G. Stark,et al.  The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction , 1993, Nature.

[40]  I. Gresser.  Can interferon induce disease? , 1982, Interferon.

[41]  J. A. Acree.  On mutation , 1980 .

[42]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.

[43]  M. Aguet,et al.  A novel member of the interferon receptor family complements functionality of the murine interferon γ receptor in human cells , 1994, Cell.

[44]  A. Wilks,et al.  Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. , 1995, Blood.

[45]  R. Schreiber,et al.  Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway , 1996, Cell.

[46]  W. Paul.  Interleukin-4: a prototypic immunoregulatory lymphokine. , 1991, Blood.

[47]  D. Hilton,et al.  Growth Hormone Preferentially Induces the Rapid, Transient Expression of SOCS-3, a Novel Inhibitor of Cytokine Receptor Signaling* , 1998, The Journal of Biological Chemistry.

[48]  T. Taniguchi,et al.  Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. , 1994, Science.

[49]  J. Flier,et al.  Identification of SOCS-3 as a potential mediator of central leptin resistance. , 1998, Molecular cell.

[50]  H. Dickensheets,et al.  Interleukin-10 Inhibits Expression of Both Interferon – and Interferon γ– Induced Genes by Suppressing Tyrosine Phosphorylation of STAT1 , 1999 .

[51]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[52]  M. Newport,et al.  A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. , 1996, The New England journal of medicine.

[53]  Suzanne Cory,et al.  bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship , 1991, Cell.

[54]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[55]  M. Aguet,et al.  Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. , 1981, The American journal of pathology.

[56]  G. Stark,et al.  Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-& gamma; signal transduction pathway , 1993, Nature.

[57]  K. Shuai,et al.  The Suppressor of Cytokine Signaling (SOCS) 1 and SOCS3 but Not SOCS2 Proteins Inhibit Interferon-mediated Antiviral and Antiproliferative Activities* , 1998, The Journal of Biological Chemistry.

[58]  J. Ihle,et al.  Naturally occurring dominant negative variants of Stat5 , 1996, Molecular and cellular biology.

[59]  S. Akira,et al.  Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.

[60]  C. Nathan,et al.  Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase , 1995, Cell.

[61]  B. Cohen,et al.  The human interferon α β receptor: Characterization and molecular cloning , 1994, Cell.

[62]  A. Billiau,et al.  Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice , 1995, Infection and immunity.

[63]  A. Elefanty,et al.  Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[65]  K. Ozato,et al.  MONOCLONAL ANTIBODIES TO MOUSE MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGENS: IV. A SERIES OF HYBRIDOMA CLONES PRODUCING ANTI‐H-2d ANTIBODIES AND AN EXAMINATION OF EXPRESSION OF H‐2d ANTIGENS ON THE SURFACE OF THESE CELLS , 1982, Transplantation.

[66]  W. Alexander,et al.  Twenty proteins containing a C-terminal SOCS box form five structural classes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[67]  P. Massa,et al.  The role of protein tyrosine phosphatase SHP-1 in the regulation of IFN-gamma signaling in neural cells. , 1996, Journal of immunology.

[68]  R. Zinkernagel,et al.  Immune response in mice that lack the interferon-gamma receptor. , 1993, Science.

[69]  R. Tatake,et al.  Regulated Expression of the Major Histocompatibility Complex Class I Genes , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.